StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Cromoglicinsure

Cromolyn

HCID 2882
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
16110-51-3
Standard-SMILES
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
InChIKey
IMZMKUWMOSJXDT-UHFFFAOYSA-N
Summenformel
C23H16O11
Durchschnittliche Molmasse
468,4 g/mol
Monoisotopische Masse
468,06926132

Überblick

Cromoglycic acid is a dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer. It has a role as a calcium channel blocker and an anti-asthmatic drug. It is a member of chromones and a dicarboxylic acid. It is a conjugate acid of a cromoglycate(1-).

Namen und Bezeichner

Bevorzugter Name
Cromolyn
IUPAC
5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid
Lokaler Name
Cromoglicinsure
Englischer Name
Cromoglicic acid
Summenformel
C23H16O11
Molmasse
468.37

Namen und Synonyme

cromolynCromoglicic acid16110-51-3Cromoglycic acidCromoglicateAcido cromoglicicoAcide cromogliciqueAcidum cromoglicicumCromo-Comod5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acidY0TK0FS77W1,3-Bis(2-carboxychromon-5-yloxy)-2-hydroxypropane
Weitere Namen anzeigen
DSCGs(4-oxo-CromoglycilCROMOLYN SODIUMClomoglicic acidSODIUM CROMOGLICATECROMOLYN SODIUM SALT
R03BC01DTXSID4022860CHEBI:597731,3-Di(2-carboxy-4-oxochromen-5-yloxy)propan-2-ol5,5'-(2-Hydroxytrimethylenedioxy)bis(4-oxochromene-2-carboxylic acid)4H-1-Benzopyran-2-carboxylic acid, 5,5'-((2-hydroxytrimethylene)dioxy)bis(4-oxo-5-{3-[(2-carboxy-4-oxo-4H-chromen-5-yl)oxy]-2-hydroxypropoxy}-4-oxo-4H-chromene-2-carboxylic acid5-(3-((2-Carboxy-4-oxo-4H-chromen-5-yl)oxy)-2-hydroxypropoxy)-4-oxo-4H-chromene-2-carboxylic acid

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1,9
Polarare Oberfläche (TPSA)
166 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
11
Frei drehbare Bindungen
8
Schwere Atome
34
Formalladung
0
Komplexität
835

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 3 Einträge

Log P= 1.92 at pH 1.2; Log P= -4.80 at pH 7.4

1.6

1.92

Color/FormColorless crystals from ethanol + ether
Solubility · 3 Einträge

ODORLESS; HYGROSCOPIC; TASTELESS BUT WITH SLIGHTLY BITTER AFTERTASTE; MELTS @ ABOUT 261 °C; INSOL IN ORG SOLVENTS; DOES NOT EXHIBIT POLYMORPHISM; PKA DIFFICULT TO MEASURE BUT BELIEVED BY ANALOGY WITH SIMILAR MONOCHROMES TO BE ABOUT 1.5 TO 2; SOME DEGRADATION PRODUCTS CAN BE DETECTED AFTER PROLONGED EXPOSURE TO UV LIGHT; UNSTABLE IN ALKALINE SOLN /CROMOLYN DISODIUM/

100 MG SOL IN 1 ML WATER @ 20 °C; PRACTICALLY INSOL IN CHLOROFORM & ALCOHOL /CROMOLYN DISODIUM/

3.58e-02 g/L

Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Anti-Allergic Agents; Anti-Asthmatic Agents

Pharmaceuticals

Melting Point · 3 Einträge

241-242 °C (decomposes)

WHITE OR CREAMY-WHITE POWDER; MP: 241-242 °C (DECOMPOSES)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Gefahrenhinweise

Other Safety InformationIMAP assessments - 4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-: Human health tier I assessment
FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Special Reports · 4 Einträge

Lourwood DL; Am Pharm 35 (6): 16-24 (1995). Treatment of chronic diseases during pregnancy.

Zsamboki G; East Pharm 38: 41-4 (1995). Pharmacology of sodium cromoglycate.

Sly RM; Ann Allergy 73 (5): 439-43 (1994). Changing asthma mortality and sales of inhaled bronchodilators and anti-asthmatic drugs.

Boulet LP; Rev Mal Respir 9 (1): 99-101 (1992). Review of North American studies on nedocromil sodium.

Sicherheit und Schutzausrüstung

Storage Conditions · 1 Eintrag

Oral cromolyn sodium capsules should be stored in tight containers at 15 to 30 °C. Capsules containing cromolyn sodium powder for oral inhalation should be stored at room temperature in tight, light-resistant containers; exposure to excessive moisture and to temperatures greater than 40 °C should be avoided. ... Cromolyn sodium aerosol for oral inhalation should be stored at 2 to 30 °C. /Cromolyn sodium/

Disposal Methods · 1 Eintrag

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

S01GX01

A - Alimentary tract and metabolism

R - Respiratory system

R - Respiratory system

D - Dermatologicals

S - Sensory organs

Pharmacodynamics · 1 Eintrag

Cromoglicate or cromolyn (USAN), a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Cromoglicate is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis.

Mechanism of Action · 6 Einträge

Cromoglicate inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Cromoglicate also may reduce the release of inflammatory leukotrienes. Cromoglicate may act by inhibiting calcium influx.

One important action of cromolyn is believed to be the inhibition of pulmonary mast cell degranulation in response to a variety of stimuli, including the interaction between cell-bound IgE and specific antigen. ... The release of histamine and other granular contents, as well as the production of leukotrienes, can be shown to be markedly reduced in vitro by cromolyn. However, its efficacy and potency are highly dependent on the source of the mast cells.

... Attention has been focused on the ability of cromolyn to reverse various functional changes in leukocytes obtained from the blood of asthmatic subjects undergoing allergen challenge, such as increased expression of membrane-bound receptors.

... Low concentrations (100 nM) of cromolyn can suppress completely the activation effects of chemoattractant peptides of human neutrophils, eosinophils, or monocytes.

The mechanisms of action of cromolyn remain relatively poorly defined. Most attention has been focused on the ability of cromolyn to reduce the accumulation of intracellular Ca +2 induced by antigen in sensitized mast cells. One biochemical correlate of the reduction of histamine release from mast cells by cromolyn is the enhanced phosphorylation of a 78,000-dalton protein. Unfortunately, these observations have been made using rather high concn of cromolyn (50 to 200 uM), and their relationship to therapeutic response has yet to be established.

Zugehörige Reaktionen

9
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 172092
HRID 172092als Edukt
Reaktionsgleichung von HRID 489088
HRID 489088als Produkt
Reaktionsgleichung von HRID 489089
HRID 489089als Edukt
Reaktionsgleichung von HRID 990013
HRID 990013als Produkt
Reaktionsgleichung von HRID 990014
HRID 990014als Edukt
Reaktionsgleichung von HRID 1170677
HRID 1170677als Produkt
Reaktionsgleichung von HRID 1170678
HRID 1170678als Edukt
Reaktionsgleichung von HRID 1790839
HRID 1790839als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
16110-51-3
PubChem CID
2882
DTXSID
DTXSID4022860
ChEMBL
CHEMBL428880
ChEBI
CHEBI:59773
UNII
Y0TK0FS77W
EC Number
240-279-8
Nikkaji
J9.027A

241 - 242 °C

Physical DescriptionSolid
Stability/Shelf LifeVERY STABLE WITH NO DEGRADATION UNDER NORMAL STORAGE CONDITIONS EXCEPT FOR MOISTURE GAIN /DISODIUM/
Dissociation Constants · 2 Einträge

1.1

pKa= 1.10

Collision Cross Section · 2 Einträge

186.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID7044554]

207.82 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental PropertiesHIGHLY POLAR; LIPID-SOLUBLE @ PKA= 1.9 /CROMOLYN DISODIUM/

Physikochemische Eigenschaften

Schmelzpunkt
241 · 241-242°C
Siedepunkt
752.3 · 752.3±60.0 °C(Predicted)
Dichte
1.623 · 1.623
storage temp.
2 · 2-8°C
pka
2 · pKa 2.0 (Uncertain)
Aggregatzustand
Solid
Farbe
Off-white to light yellow
CAS Datenbank
16110 · 16110-51-3(CAS DataBase Reference)
EPA chemische Informationen
Cromolyn (16110-51-3)

Toxikologische Informationen

Interactions · 5 Einträge

Studies demonstrating a lack of ion pair formation between sodium cromoglycate (cromolyn sodium) and alkylbenzdimethylamonium ions in rat intestine are briefly discussed. /Cromolyn sodium/

An analysis of the absorption and desorption isotherms for sodium cromoglycate (cromolyn sodium) and cromolyn sodium lactose moisture uptake is presented. Up to 15% moisture content had no effect on the tensile and shear properties of cromolyn sodium, due to adsorption into the interior of cromolyn sodium, leaving little absorbed moisture on the surface of the particles.

The mechanism of action of the mast cell stabilizers sodium cromoglycate and FPL-52694 as protective agents against ethanol induced gastric mucosal damage was investigated in the rat. Using an ex vivo gastric chamber model, various concn (l0-80 mg/ml) of the two agents were applied to the gastric mucosa prior to exposure to 40% ethanol. Both agents significantly reduced ethanol induced damage in a dose dependent manner. When given orally (80 mg/kg) both agents significantly reduced gastric damage induced by subsequent oral administration of absolute ethanol. Pretreatment with indomethacin did not significantly affect the protection afforded by FPL-52694, but did cause a partial reversal of the protective effect of sodium cromoglycate. Changes in gastric leukotriene C4 synthesis did not correlate with the protective effects of the two agents. Both mucosal and connective tissue mast cell numbers were significantly reduced following oral ethanol administration. In the groups pretreated with FPL-52694 or sodium cromoglycate, mucosal mast cell numbers were not significantly different from those in rats not treated with ethanol. Furthermore, the connective tissue mast cell numbers were significantly lower than in ethanol treated control rats, despite a greater than 95% reduction of ethanol induced hemorrhagic damage. These results therefore suggest that stimulation of gastric prostaglandin synthesis is not important in the mechanism of action of FPL-52694, and neither agent appears to reduce damage through a mechanism related to effects on gastric leukotriene C4 synthesis. The present studies further suggest that the protection afforded by pretreatment with sodium cromoglycate or FPL-52694 may be unrelated to effects of these agents on the connective tissue mast cell population in the stomach. /Sodium cromoglycate/

The effect of histamine on the absorption and clearance of inhaled cromolyn sodium (sodium cromoglycate) was examined in 7 mildly asthmatic patients with hyperresponsive airways and 8 normal subjects who inhaled either placebo or histamine followed by cromolyn. In the asthmatic group histamine inhalation led to a mean 24% reduction in the forced expiratory volume in 1 second but had no effect on the normal subjects. When compared with the inhaled placebo, histamine incr the initial pulmonary absorption of cromolyn without influencing the total amount of drug absorbed in both asthmatics and normals. These observations suggest that the pharmacokinetics of the inhaled drug may be altered significantly by inflammatory mediators present at the site of drug absorption from the airways. /Cromolyn sodium/

For more Interactions (Complete) data for CROMOLYN (9 total), please visit the HSDB record page.

Human Toxicity Excerpts...CROMOLYN IS VIRTUALLY NONTOXIC. ACUTE OVERDOSAGE HAS NOT BEEN REPORTED &, OTHER THAN A FEW ALLERGIC REACTIONS, SERIOUS ADVERSE EFFECTS APPEAR RARE. /CROMOLYN DISODIUM/
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Cromoglicate

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5 Einträge

...INCR FETAL RESORPTION & DECR FETAL WEIGHT /IN ANIMALS/ WERE OBSERVED @ DOSAGES THAT PRODUCED MATERNAL TOXICITY. /CROMOLYN DISODIUM/

RENAL TOXICITY HAS BEEN REPORTED IN ANIMALS... /CROMOLYN DISODIUM/

NO TERATOGENIC EFFECTS HAVE BEEN REPORTED IN ANIMALS, EVEN AFTER DAILY IV ADMIN OF ENORMOUS DOSES OF CROMOLYN THROUGHOUT PREGNANCY. /CROMOLYN DISODIUM/

Reproduction studies in mice, rats, and rabbits with cromolyn administered parenterally in doses of up to 338 times the human clinical dose showed no evidence of fetal malformations. Adverse fetal effects (increased resorptions and decreased fetal weight) were noted only with very high parenteral doses that produced maternal toxicity.

For more Non-Human Toxicity Excerpts (Complete) data for CROMOLYN (6 total), please visit the HSDB record page.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Cromolyn

18.6

78.9

For adults and adolescents (13 years and older), the dosage is two ampules four times daily, taken one-half hour before meals and at bedtime. Each ampule contains 100 mg/5 mL cromolyn sodium oral solution.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 800 mg/day, Lowest Therapeutic Dose (LTD): 10.0 mg/kg-day, and Screening Dose: 0.003 mg/kg-day.

26-Nov-21

Regulatorische Informationen

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Sicherheitsdaten

wgk
2
RTECS-Nr.
DJ2380000
risk_code
36/37/38
Toxizität
rat,LD50,oral,> 2150mg/kg (2150mg/kg),United States Patent Document. Vol. #4407810,
hazard_code
Xi
safety_code
26-36
Giftige Stoffe Daten
16110-51-3(Hazardous Substances Data)

For more Mechanism of Action (Complete) data for CROMOLYN (6 total), please visit the HSDB record page.

Biological Half-Life · 2 Einträge

1.3 hours

FATE OF CROMOLYN WAS EXAMINED IN 12 ASTHMATIC PATIENTS. AVG PLASMA T/2 WAS 81 MIN.

Metabolism/MetabolitesNO METABOLITES WERE DETECTED IN MAN & IN NINE MAMMALIAN SPECIES AFTER ORAL & IV ADMIN. /CROMOLYN DISODIUM/
FDA Pharmacological Classification · 5 Einträge

Y0TK0FS77W

CROMOLYN

Physiologic Effects [PE] - Decreased Histamine Release

Established Pharmacologic Class [EPC] - Mast Cell Stabilizer

Cromolyn is a Mast Cell Stabilizer. The physiologic effect of cromolyn is by means of Decreased Histamine Release.

MeSH Pharmacological Classification · 2 Einträge

Compounds that prevent the release of inflammatory mediators from MAST CELLS.

Drugs that are used to treat asthma.

Absorption, Distribution and Excretion · 6 Einträge

1%

MOST OF ABSORBED DRUG IS EXCRETED UNCHANGED BY LIVER & KIDNEYS WITHIN A FEW DAYS & NONE APPEARS TO UNDERGO METABOLIC DEGRADATION. THE UNABSORBED PORTION (APPROX 80%) IS RECOVERABLE FROM FECES. FOLLOWING INHALATION, MAX PLASMA LEVEL...REACHED WITHIN SEVERAL MIN, & PLASMA T1/2 IS ONE TO ONE-HALF HOURS. /CROMOLYN DISODIUM/

THE AMT OF CROMOLYN...ABSORBED INTO BLOODSTREAM FOLLOWING INHALATION OF A DOSE OF 20 MG DOES NOT APPEAR TO EXERT ANY GENERALIZED PHARMACOLOGIC EFFECTS. /CROMOLYN DISODIUM/

THE SMALL AMT OF CROMOLYN THAT IS ABSORBED IS EXCRETED UNCHANGED BY LIVER & KIDNEYS... APPROX 10% OF A 20% MG DOSE...MAY REMAIN IN INHALER AFTER PATIENTS /USE/ &...APPROX 8% OF DOSE IS ABSORBED INTO BLOODSTREAM (PRIMARILY BY LUNG BUT ALSO BY GI TRACT). /CROMOLYN DISODIUM/

FATE OF CROMOLYN WAS EXAMINED IN 12 ASTHMATIC PATIENTS. MAX PLASMA CONCN (MEAN 9.2 NG/ML OBTAINED WITHIN 15 MIN OF INHALING 20 MG). ABSORPTION FROM LUNG IS RAPID, MOST OF INHALED DOSE IS SWALLOWED.

For more Absorption, Distribution and Excretion (Complete) data for CROMOLYN (10 total), please visit the HSDB record page.

Cellular LocationsMembrane

Verwendung und Herstellung

Uses · 3 Einträge

MEDICATION

MEDICATION (VET)

Use (kg; approx.) in Germany (2009): >750

Methods of Manufacturing · 2 Einträge

2,6-DIHYDROXYACETOPHENONE /REACTS/ WITH EPICHLOROHYDRIN IN PRESENCE OF BASIC CATALYST TO YIELD... 2'2'''-((2-HYDROXYTRIMETHYLENE)DIOXY)BIS(6'-HYDROXYACETOPHENONE). REACTION WITH DIETHYL OXALATE EFFECTS DEHYDRATION & DEETHANOLATION OF EACH HYDROXYACETOPHENONE PORTION.../ETHYL ESTERS ARE/...SAPONIFIED WITH NAOH. /2NA/

2,6-Dihydroxyacetaphenone + epichlorohydrin + diethyl oxalate (epoxidation/ether formation/condensation/saponification)

Formulations/Preparations · 3 Einträge

DSCG, SODIUM CHROMOGLYCATE /CROMOLYN DISODIUM/

CROMOLYN SODIUM SALT /CROMOLYN DISODIUM/

Cromolyn sodium, disodium cromoglycate, DSCG, FPL-670, Aarane, Alercrom, Alerion, Allergocrom, Colimune, Cromovet, Fivent, Gastrofrenal, Inostral, Intal, Introl, Irtan, Lomudal, Lomupren, Lomusol, Lomuspray, Nalcrom, Nalcron, Nasalcrom, Nasmil, Opticrom, Opticron, Rynacrom, Sofro, Vividrin /Cromolyn disodium/

Use ClassificationPharmaceuticals
General Manufacturing Information · 2 Einträge

US PATENT 3,419,578. /CROMOLYN DISODIUM/

Available commercially as the disodium salt.

Anwendungen · 2 Einträge

BeschreibungCromolyn is a synthetic analog of the plant extract khellin that was first developed in the late 1960s and introduced into clinical practice the following decade. It is continued to be used widely in the treatment of allergic rhinitis, asthma, mastocytosis, and conjunctivitis. It has an outstanding safety profile and can be readily obtained without prescription in many countries.

VerwendenAnti Asthamatic

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

NatriumhydroxidDiethyloxalat1-Chlor-2,3-epoxypropan

Ergänzende Hinweise

DefinitionChEBI: A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.